<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:56:31Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4411703" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4411703</identifier><datestamp>2015-04-29</datestamp><setSpec>bmcmd</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id>
      <journal-title-group>
        <journal-title>BMC Medical Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2350</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4411703</article-id>
      <article-id pub-id-type="pmcid">PMC4411703</article-id>
      <article-id pub-id-type="pmc-uid">4411703</article-id>
      <article-id pub-id-type="pmid">25524009</article-id>
      <article-id pub-id-type="pmid">25524009</article-id>
      <article-id pub-id-type="publisher-id">139</article-id>
      <article-id pub-id-type="doi">10.1186/s12881-014-0139-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mutations in <italic>NFKB2</italic> and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Brue</surname>
            <given-names>Thierry</given-names>
          </name>
          <address>
            <email>Thierry.BRUE@ap-hm.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quentien</surname>
            <given-names>Marie-HÃ©lÃ¨ne</given-names>
          </name>
          <address>
            <email>marie-helene.quentien@univ-amu.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khetchoumian</surname>
            <given-names>Konstantin</given-names>
          </name>
          <address>
            <email>Konstantin.Khetchoumian@ircm.qc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bensa</surname>
            <given-names>Marco</given-names>
          </name>
          <address>
            <email>mbensa@ausl-cesena.emr.it</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Capo-Chichi</surname>
            <given-names>JosÃ©-Mario</given-names>
          </name>
          <address>
            <email>jose.capo-chichi@umontreal.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Delemer</surname>
            <given-names>Brigitte</given-names>
          </name>
          <address>
            <email>bdelemer@chu-reims.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Balsalobre</surname>
            <given-names>Aurelio</given-names>
          </name>
          <address>
            <email>aurelio.balsalobre@ircm.qc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nassif</surname>
            <given-names>Christina</given-names>
          </name>
          <address>
            <email>christina.nassif@recherche-ste-justine.qc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Papadimitriou</surname>
            <given-names>Dimitris T</given-names>
          </name>
          <address>
            <email>DTPapadimitriou@in.gr</email>
          </address>
          <xref ref-type="aff" rid="Aff7"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pagnier</surname>
            <given-names>Anne</given-names>
          </name>
          <address>
            <email>APagnier@chu-grenoble.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff8"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hasselmann</surname>
            <given-names>Caroline</given-names>
          </name>
          <address>
            <email>chasselmann@mac.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patry</surname>
            <given-names>Lysanne</given-names>
          </name>
          <address>
            <email>lyspatry@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schwartzentruber</surname>
            <given-names>Jeremy</given-names>
          </name>
          <address>
            <email>jeremy37@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souchon</surname>
            <given-names>Pierre-FranÃ§ois</given-names>
          </name>
          <address>
            <email>pfsouchon@chu-reims.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takayasu</surname>
            <given-names>Shinobu</given-names>
          </name>
          <address>
            <email>Shinobu.Takayasu@ircm.qc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Enjalbert</surname>
            <given-names>Alain</given-names>
          </name>
          <address>
            <email>alain.enjalbert@univ-amu.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Van Vliet</surname>
            <given-names>Guy</given-names>
          </name>
          <address>
            <email>guy.van-vliet@recherche-ste-justine.qc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff10"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Majewski</surname>
            <given-names>Jacek</given-names>
          </name>
          <address>
            <email>jacek.majewski@mcgill.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Drouin</surname>
            <given-names>Jacques</given-names>
          </name>
          <address>
            <email>Jacques.Drouin@ircm.qc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Samuels</surname>
            <given-names>Mark E</given-names>
          </name>
          <address>
            <email>mark.e.samuels@umontreal.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff11"/>
        </contrib>
        <aff id="Aff1"><label/>Aix-Marseille University, Centre de Recherche en Neurobiologie et Neurophysiologie de Marseille (CRN2M), Centre National de la Recherche Scientifique, UnitÃ© Mixte de Recherche 7286, FacultÃ© de MÃ©decine de Marseille, 13344 Marseille, France </aff>
        <aff id="Aff2"><label/>Assistance Publique-HÃ´pitaux de Marseille (APHM), Department of Endocrinology, Centre de RÃ©fÃ©rence des Maladies Rares dâOrigine Hypophysaire, HÃ´pital de la Timone, 13005 Marseille, France </aff>
        <aff id="Aff3"><label/>Laboratoire de GÃ©nÃ©tique molÃ©culaire, Institut de recherches cliniques de MontrÃ©al, 110 Avenue des Pins Ouest, MontrÃ©al, QC H2W 1R7 Canada </aff>
        <aff id="Aff4"><label/>Ospedale Bufalini, Department of Paediatrics, Cesena, FC Italy </aff>
        <aff id="Aff5"><label/>Centre de Recherche du CHU Ste-Justine, 3175 Cote Ste-Catherine, Montreal, QC Canada </aff>
        <aff id="Aff6"><label/>Departments of Endocrinology and of Pediatrics, Centre Hospitalier Robert DebrÃ©, 51092 Reims, France </aff>
        <aff id="Aff7"><label/>Department of Pediatric-Adolescent Endocrinology and Diabetes, Athens Medical Center, Athens, Greece </aff>
        <aff id="Aff8"><label/>Clinique universitaire de pÃ©diatrie, CHU de Grenoble, Grenoble, France </aff>
        <aff id="Aff9"><label/>Department of Human Genetics, McGill University, Montreal, QC Canada </aff>
        <aff id="Aff10"><label/>Endocrinology Service and Research Center, Department of Pediatrics, CHU Ste-Justine, University of Montreal, Montreal, QC Canada </aff>
        <aff id="Aff11"><label/>Department of Medicine, University of Montreal, Montreal, QC Canada </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>139</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>9</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© Brue et al.; licensee BioMed Central. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>DAVID syndrome is a rare condition combining anterior pituitary hormone deficiency with common variable immunodeficiency. <italic>NFKB2</italic> mutations have recently been identified in patients with ACTH and variable immunodeficiency. A similar mutation was previously found in <italic>Nfkb2</italic> in the immunodeficient <italic>Lym1</italic> mouse strain, but the effect of the mutation on endocrine function was not evaluated.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We ascertained six unrelated DAVID syndrome families. We performed whole exome and traditional Sanger sequencing to search for causal genes. <italic>Lym1</italic> mice were examined for endocrine developmental anomalies.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Mutations in the <italic>NFKB2</italic> gene were identified in three of our families through whole exome sequencing, and in a fourth by direct Sanger sequencing. <italic>De novo</italic> origin of the mutations could be demonstrated in three of the families. All mutations lie near the C-terminus of the protein-coding region, near signals required for processing of NFÎB2 protein by the alternative pathway. Two of the probands had anatomical pituitary anomalies, and one had growth and thyroid hormone as well as ACTH deficiency; these findings have not been previously reported. Two children of one of the probands carried the mutation and have to date exhibited only an immune phenotype. No mutations were found near the C-terminus of <italic>NFKB2</italic> in the remaining two probands; whole exome sequencing has been performed for one of these. <italic>Lym1</italic> mice, carrying a similar <italic>Nfkb2</italic> C-terminal mutation, showed normal pituitary anatomy and expression of proopiomelanocortin (<italic>POMC</italic>).</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>We confirm previous findings that mutations near the C-terminus of <italic>NFKB2</italic> cause combined endocrine and immunodeficiencies. <italic>De novo</italic> status of the mutations was confirmed in all cases for which both parents were available. The mutations are consistent with a dominant gain-of-function effect, generating an unprocessed <italic>NFKB2</italic> super-repressor protein. We expand the potential phenotype of such <italic>NFKB2</italic> mutations to include additional pituitary hormone deficiencies as well as anatomical pituitary anomalies. The lack of an observable endocrine phenotype in <italic>Lym1</italic> mice suggests that the endocrine component of DAVID syndrome is either not due to a direct role of NFKB pathways on pituitary development, or else that human and mouse pituitary development differ in its requirements for NFKB pathway function.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1186/s12881-014-0139-9) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Deficit in anterior pituitary function (hypopituitarism) and common variable immune deficiency (CVID, MIM [607594]) represent two very different clinical presentations. Mutations in several genes have been associated with each of these conditions, but until recently no gene has been associated with deficiencies in both systems in the same patients. Several years ago we identified such patients in three families as part of a national screen for hypopituitarism in France, and defined a novel disorder which we named DAVID syndrome (for Deficient Anterior pituitary with Variable Immune Deficiency) [<xref ref-type="bibr" rid="CR1">1</xref>]. At the time it was not obvious whether these patients represented a shared molecular etiology or a coincidental overlap of two otherwise uncommon pediatric conditions, although there were at least two previous isolated case reports with similar clinical descriptions [<xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref>]. Chen <italic>et al</italic> recently reported mutations in the <italic>NFKB2</italic> gene in two families from Utah with features consistent with our definition of DAVID syndrome (immunodeficiency with hypogammaglobulinemia, plus central pituitary deficiency), one mutation of which was consistent with <italic>de novo</italic> germ line origin [<xref ref-type="bibr" rid="CR4">4</xref>]. Several additional groups have since reported mutations near the C-terminus of <italic>NFKB2</italic>, in patients with features overlapping DAVID syndrome, although not all patients showed the endocrine aspect of the phenotype [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR7">7</xref>].</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Methods</title>
      <p>Research ethics approval was obtained from the review boards of the Centre de Recherche du CHU Ste-Justine, and of the Assistance Publique-HÃ´pitaux de Marseille. Written informed consent for the study and for publication of the patientsâ anonymous details and images were obtained from the participants or their parents. Clinical studies were performed as described in the Additional file <xref rid="MOESM1" ref-type="media">1</xref>. All experimental procedures with laboratory animals were approved by the IRCM Animal Protection Committee and followed guidelines and regulations of the Canadian Council of Animal Care. Whole exome sequencing on DNA from peripheral blood leukocytes was performed using standard methods and as previously described (see Additional file <xref rid="MOESM1" ref-type="media">1</xref> for additional details) [<xref ref-type="bibr" rid="CR8">8</xref>]. PCR-based Sanger sequencing with fluorescent capillary electrophoresis was performed using standard methods, and results were visualized using Mutation Surveyor (Soft Genetics, Inc.) Numbering in this study refers to Refseq entry NM_001077494.3, equivalent to isoform a, consistent with the usual amino acid numbering in functional studies of NFKB2 protein and the non-canonical processing pathway. Nucleotide numbering for mutations begins at the first A of the initiating methionine ATG.</p>
      <p><italic>Lym1</italic> mice were obtained from the Walter and Eliza Hall Institute (Victoria, Australia). Histology and immunohistochemistry were performed as previously described [<xref ref-type="bibr" rid="CR9">9</xref>]. See Additional file <xref rid="MOESM1" ref-type="media">1</xref> for additional details.</p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>Results and discussion</title>
      <p>Our original French probands, recruited from different geographic regions through the âGenhypopitâ network, [<xref ref-type="bibr" rid="CR10">10</xref>] were noted to have immunodeficiencies of varying severity with recurrent childhood infections and hypogammaglobulinemia, in addition to ACTH deficiency (patients A1, B1, C1, C2, see FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>, our original publication for full clinical details, and Additional file <xref rid="MOESM1" ref-type="media">1</xref> for updated phenotypes; C2 was deceased prior to this study) [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients A2, A3 and C3 had immune but not endocrine deficiencies. Patient C1 also had a growth hormone deficiency, and this patient has since developed central (<italic>i.e.</italic> not thyroidal) hypothyroidism. The endocrine deficiencies appear to be longstanding, not acute secondary to current infections. MRI scans of the pituitary were performed for the probands, with hypoplasia observed for patient B1 but not A1 or C1 (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1A, B, C1, 2). Since the original report, two new carriers were ascertained in family A, A5 and A6 (see below and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1 for clinical details).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>DAVID syndrome families and</bold>
<bold><italic>NFKB2</italic></bold>
<bold>gene structure with mutations. A-D</bold>, pedigrees showing genotypes of sequenced individuals. Symbols: Filled, immunodeficiency, ACTH deficiency, GH deficiency; lower half filled, immunodeficiency; lower half plus upper left quadrant filled, immunodeficiency, ACTH deficiency; open, unaffected or unknown. n.a. DNA and clinical information not available. +/+, no mutation at any of the three sites found in the families. <bold>E</bold>, structure of the NFÎºB2 protein (isoform A numbering), indicating the major functional domains, regulated phosphorylated serines 866 and 870, and sites of mutations reported here, by Chen, Liu, Lee, Lindsley <italic>et al</italic>, or at the orthologous site in the <italic>Lym</italic>1 mouse (Tucker <italic>et al</italic>). The vertical arrow above the domain cartoon indicates approximate site of proteolytic cleavage of p100, which releases the amino-terminal p52 active fragment. RHD, rel homology domain; ARDs, ankyrin repeat domains; DD, death domain; NRD, NIK response domain.</p></caption><graphic xlink:href="12881_2014_139_Fig1_HTML" id="MO1"/></fig></p>
      <p>We performed whole exome sequencing on DNA from A1, B1 and C1. In the exome data, only one gene carried a rare, protein-altering variant in all three probands, the gene <italic>NFKB2</italic> (MIM [164012]). In <italic>NFKB2</italic>, proband A1 was heterozygous for missense mutation p.A867V, proband B1 was heterozygous for missense mutation p.D865G, and proband C1 was heterozygous for an 8Â bp frameshift deletion, p.R853Afs*29 (FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>A, B, C). All three mutations were verified by PCR-based Sanger fluorescent sequencing (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S3A-E). Sequencing confirmed that both parents were negative in peripheral blood DNA for the mutations found in the probands in families B and C, as was the one sampled parent in family A. In families A and B, all of the sampled unaffected relatives were negative for the familial mutation (data not shown). Two children of A1, A5 and A6, were heterozygous for the familial mutation (data not shown). One child (A6) showed a clinical phenotype with recurrent infections and immunodeficiency, while A5 had moderate immunoglobulin deficiency with no clinical signs as yet. In family C, affected sibling C3 of the proband also carried the familial mutation. No additional pathogenic variants were found in any of the probands in targeted exons of genes otherwise known to cause hypopituitarism (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>). There were rare protein-altering variants detected in several other genes associated with common variable or severe immunodeficiency, some in B1 and some in C1, but none in any two probands together (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p>
      <p>A fourth patient with DAVID syndrome was independently ascertained, previously only reported in abstract form [<xref ref-type="bibr" rid="CR11">11</xref>]. This patient (D1, see FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: S2)) was asthenic with immunodeficiency from an early age, suffered hair loss and onychodystrophy, and had low ACTH before and after CRH stimulation. All other pituitary functions were normal, and MRI showed hypoplastic anterior pituitary (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1D, see Additional file <xref rid="MOESM1" ref-type="media">1</xref> for more details). The two C-terminal coding exons of <italic>NFKB2</italic> were directly sequenced in DNA from patient D1, using PCR-based Sanger technology. The patient was heterozygous for a truncating mutation also at amino acid position 853, p.R253X (FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>D). This was not the same as the frameshift mutation at the same residue in family C. The mutation was not present in blood DNA from either parent (data not shown).</p>
      <p>All variants have been submitted to ClinVar and assigned preliminary accession numbers pending database curation: c.2556_2563del SCV000172085; c.2594Aâ&gt;âG SCV000172086; c.2600Câ&gt;âT SCV000172087; c.2557Câ&gt;âT SCV000172088.</p>
      <p>Our genetic findings strongly implicate <italic>NFKB2</italic> as the causal gene for DAVID syndrome in our patients, particularly taking into account similar mutations found by two other groups in similar patients. In all we identified four different heterozygous mutations, two protein-truncating and two missense variants, near the C-terminus of the protein coding region of <italic>NFKB2</italic>, a region required for the correct processing of the primary translation product (FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>E) [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>]. In the three families (B, C, D) where both parents could be sampled, neither parent carried the mutation in DNA from peripheral lymphocytes, consistent with the mutations being germline <italic>de novo</italic>; family A with only one parent available is also compatible with this model of transmission. The occurrence of two affected siblings in family C is completely consistent with the proposed <italic>de novo</italic> germ line origin of the mutations. Although uncommon, such mutations may arise in mitotic germ line clones, either in testes or ovaries, and clonally expand, giving rise to mutation-carrying post-meiotic gametes repeatedly, potentially over a period of years. Intrafamilial recurrence in multiple affected siblings with presumptive <italic>de novo</italic> pre-meiotic germ line origin has been reported in numerous studies of unrelated genetic disorders [<xref ref-type="bibr" rid="CR14">14</xref>-<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>The mutation in family B of Chen <italic>et al</italic> is identical to the mutation in our family D at the nucleotide and protein level (p.R253X, FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>E) [<xref ref-type="bibr" rid="CR4">4</xref>]. These probably represent independent mutational events, although the ethnicity of their family was not reported. In the family reported by Liu <italic>et al.</italic>, the phenotype co-segregates with a frameshift mutation beginning one amino acid upstream of phosphorylated serine 865. It should be noted that hypoplastic pituitary anatomy as visualized by MRI was not reported by either Chen or Liu <italic>et al</italic>, whereas two of our patients have anatomical pituitary defects. Similarly, the mutation p.D865G reported by Lee <italic>et al</italic> is the same as that found in our family B [<xref ref-type="bibr" rid="CR5">5</xref>]. Lee <italic>et al</italic> demonstrated that this mutation deleteriously affected NFKB2 protein processing in response to activation of the non-canonical pathway. Oddly, all three patients of Lee <italic>et al</italic> are reported to have alopecia areata, which we did not observe in our patient B1, whereas their patients lacked an overt endocrine deficiency.</p>
      <p>The unique association of ACTH deficiency with combined variable immunodeficiency in DAVID syndrome suggested that <italic>NFKB2</italic> might have a critical role in pituitary development, particularly for differentiation of ACTH-producing corticotrope cells. A similar mutation near the C-terminus of the murine <italic>Nfkb2</italic> ortholog was previously identified in a large scale mouse mutagenesis screen for cellular immunodeficiency [<xref ref-type="bibr" rid="CR19">19</xref>]. This <italic>Lym1</italic> strain shows severely reduced viability as homozygotes, although heterozygotes are viable and fertile. The mice show multiple aspects of immunodeficiency similar to DAVID syndrome, including a reduced B cell compartment and reduced antigen response with hypogammaglobulinemia and autoimmune response in heterozygotes. However the endocrine status of these mice was not previously described, nor was the anatomical development of their hypothalamus and pituitary. We assessed pituitary development in the <italic>Lym1</italic> mice at various ages. Unexpectedly, the gross morphology of pituitaries from wild-type and <italic>Lym1</italic>heterozygous or homozygous mutant pituitaries did not reveal any obvious anatomical defect either in young mice (FigureÂ <xref rid="Fig2" ref-type="fig">2</xref>A, E, I), or in older animals (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S4). Expression of <italic>Pomc</italic> was assessed using ACTH immunofluorescence, and the differentiation status of corticotropes and melanotropes was assessed using immunostaining for Tpit (Tbx19) Differentiation of anterior lobe corticotropes and intermediate lobe melanotropes appeared normal in distribution and cell numbers (FigureÂ <xref rid="Fig2" ref-type="fig">2</xref>C, G, K, S4) and expression of <italic>Pomc</italic> was not obviously affected by the <italic>Lym1</italic> mutation (FigureÂ <xref rid="Fig2" ref-type="fig">2</xref>B, F, G, S4). Histological analysis of adrenals from mice of the three genotypes also did not reveal any defect (FigureÂ <xref rid="Fig2" ref-type="fig">2</xref>D, H, L). In separate experiments using expression array profiling, we have documented that both <italic>Nfkb1</italic> and <italic>Nfkb2</italic> are expressed in the adult mouse anterior pituitary (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S5).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Histology of</bold>
<bold><italic>Lym1</italic></bold>
<bold>mutant mouse pituitaries and adrenals.</bold> HE staining of pituitaries <bold>(A, E, I)</bold> and adrenals <bold>(D, H, L)</bold> from WT <bold>(A, D)</bold>, heterozygous (<italic>Nfkb2</italic>
<sup><italic>Lym1/+</italic></sup>) or homozygous (<italic>Nfkb2</italic>
<sup><italic>Lym1/Lym1</italic></sup>) newborn mice. Staining of pituitaries with anti-ACTH <bold>(B, F, J)</bold> or anti-Tpit <bold>(C, G, K)</bold> antibodies in wild type, heterozygous, and homozygous mutant mice respectively. AL: anterior lobe, IL: intermediate lobe, PL: posterior lobe. Scale bars are shown.</p></caption><graphic xlink:href="12881_2014_139_Fig2_HTML" id="MO2"/></fig></p>
      <p>NFÎºB2 is synthesized as a large precursor (p100) that must be processed to release the active N-terminal rel-homology domain (RHD, p52). Processing of NFÎºB2 is tightly regulated via the non-canonical pathway, with most protein remaining unprocessed until the cell receives an appropriate signal via receptors such as LTÎ²R, BAFFR, RANK or CD40 [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref>]. Signalling leads to phosphorylation of specific serines near the C-terminus of NFÎºB2, including S866 and S870, via a pathway that employs the NIK and IKKA kinases [<xref ref-type="bibr" rid="CR12">12</xref>]. This in turn leads to cleavage by the proteasome to produce the RHD p52 fragment. The occurrence of missense mutations bracketing S866 in two of our families suggests that these residues are important for recognition of the site by its kinase. Unprocessed full-length NFÎºB2 p100 can act as an IÎºB-like inhibitor [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR22">22</xref>]. Mutations in <italic>NFKB2</italic> leading to a protein that is unable to proceed via the non-canonical pathway, but is otherwise functional, are therefore anticipated to generate a dominant negative repressor, which could block the action of multiple RHD-dimers. The tight clustering of six different mutations in human DAVID syndrome patients in the region of <italic>NFKB2</italic> regulated by the non-canonical pathway (FigureÂ <xref rid="Fig1" ref-type="fig">1</xref>E) is likely related to the specificity and rarity of the phenotype. It should be noted that mutations in <italic>NFKB2</italic> have not been reported in cases of isolated anterior pituitary deficiency, lacking an immunodeficiency component.</p>
      <p>The pathology we observed in the <italic>Lym1</italic> mice is inconsistent with an effect of the <italic>Nkfb2</italic> mutation in that strain at the level of primary pituitary development. Alternatively, the human endocrine phenotype might potentially result from an autoimmune reaction, consistent with the observed alopecia in several DAVID patients. <italic>Nfkb2</italic> has been shown to play a role in acquired self-tolerance in knockout mice [<xref ref-type="bibr" rid="CR23">23</xref>]. Mice accumulating p100 as a result of defects in or upstream of <italic>Nfkb2</italic> show mild osteopetrosis, [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR24">24</xref>] and the RHD system is known to play a role in bone metabolism [<xref ref-type="bibr" rid="CR25">25</xref>]. However, our DAVID syndrome patients carrying <italic>NFKB2</italic> mutations have normal bone mineral density (T. Brue and M.-H. Quentien, <italic>pers. comm</italic>.).</p>
      <p>The occurrence of GH and TSH deficiencies in our patient C1, as well as the abnormal pituitary anatomy observed in patients B1 and D1, constitute an expansion of the phenotype for this gene defect. We have previously reported that severe neonatal cortisol deficiency may be associated with transient GH deficiency [<xref ref-type="bibr" rid="CR26">26</xref>] but an association with TSH deficiency is a novel observation. The subclinical phenotype of patient A5 is indicative of variable penetrance even in the same family, or a possibly delayed onset of the phenotype. The terminology of âcentral adrenalâ deficiency in other papers describing <italic>NFKB2</italic> mutations may be overly restrictive, as the endocrine deficiencies among our patients are not restricted to hormones affecting adrenal function. A corticotropin-releasing factor test of patient D1 was consistent with a pituitary and not an hypothalamic defect.</p>
      <p>We recently ascertained a fifth case (E1) with DAVID syndrome, in an unrelated French patient with both parents unaffected (but not sampled). Sanger sequencing of the two C-terminal coding exons of <italic>NFKB2</italic> was negative for any variation. Thus the phenotype of this patient remains unexplained.</p>
      <p>A sixth, French-Canadian patient (F1), was ascertained after being hospitalized at age 17Â years for a renal granuloma with immunoglobulin M-complex glomerulonephritis, low IgG levels, and a diagnosis of possible common variable immunodeficiency [<xref ref-type="bibr" rid="CR27">27</xref>]. She was referred to Endocrinology due to primary amenorrhea and was found to have hypothalamic hypogonadism and severe ACTH and growth hormone deficiencies, although she was not of short stature [<xref ref-type="bibr" rid="CR28">28</xref>]. Pituitary MRI showed a small anterior pituitary and a thin pituitary stalk with an ectopic posterior pituitary, suggesting a congenital defect [<xref ref-type="bibr" rid="CR29">29</xref>]. Exome sequencing of DNA from this patient showed no pathogenic variants in <italic>NFKB2</italic>, whereas all coding exons of the gene were well covered. As is typical, several hundred heterozygous rare potentially pathogenic variants were identified in the complete exome analysis of this patient. The results for patients E1 and F1 suggest that genetic heterogeneity is likely for DAVID syndrome, and that variable endocrine presentation may be a hallmark of the disorder.</p>
      <p>The rel homology domain transcription factor signalling pathway is an active target of therapies for cancers especially breast and multiple myeloma [<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref>]. Our results caution that broad inhibition of these pathways, or specific inhibition of NFÎºB2 processing, could have long-term deleterious effects on central endocrine function. Monitoring endocrine function may be indicated as a component of drug trials targeting NFÎºB pathways.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>We confirm previous findings that mutations near the C-terminus of <italic>NFKB2</italic> cause combined endocrine and immunodeficiencies. <italic>De novo</italic> status of the mutations was confirmed in all cases for which both parents were available. The mutations are consistent with a dominant gain-of-function effect, generating an unprocessed <italic>NFKB2</italic> super-repressor protein. We expand the potential phenotype of such <italic>NFKB2</italic> mutations to include additional pituitary hormone deficiencies as well as anatomical pituitary anomalies. The lack of an observable endocrine phenotype in <italic>Lym1</italic> mice suggests that the endocrine component of DAVID syndrome is either not due to a direct role of NFÎB pathways on pituitary development, or else that human and mouse pituitary development differ in its requirements for NFÎB pathway function.</p>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec5">
          <title>Additional file</title>
          <p>
            <media position="anchor" xlink:href="12881_2014_139_MOESM1_ESM.pdf" id="MOESM1">
              <label>Additional file 1:</label>
              <caption>
                <p>
<bold>Clinical description of the patients.</bold>
</p>
              </caption>
            </media>
          </p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authorsâ contributions</bold>
        </p>
        <p>TB supervised clinical studies and participated in manuscript preparation. M-HQ assisted in clinical and molecular studies. KK performed mouse pathology studies. MB assisted in clinical studies. JC-C performed molecular sequencing. BD assisted with clinical studies. AB performed mouse pathology studies. CN performed technical work. DT Papadimitriou assisted with clinical studies. AP assisted with clinical studies. CH assisted with clinical studies. LP performed technical work. JS performed bioinformatic analyses. P-FS assisted with clinical studies. ST performed mouse pathology studies. AE supervised collection and handling of patient samples and participated in manuscript preparation. GVV supervised clinical studies and participated in manuscript preparation. JM supervised bioinformatic analyses and participated in manuscript preparation. JD supervised mouse pathology studies and participated in manuscript preparation. MES supervised molecular studies and performed primary manuscript preparation. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>First and foremost we thank the patients and their families for participating in this study. Thanks to Mauro Pocecco for providing clinical data on pedigree D and to Catherine Brue-Fabre for providing clinical data on pedigree E, to Cheri Deal, Johnny DeladoÃ«y and Elie Haddad for valuable discussions. Thanks to the team at the Walter and Eliza Hall Institute for assistance in obtaining the Lym1 mouse strain. MES was supported by the Centre de Recherche du CHU Ste-Justine. All sequencing was performed at the McGill University and Genome Quebec Centre for Innovation. JD is supported by grants from the Canadian Institutes of Health Research (CIHR). The FORGE Canada Consortium: Finding of Rare Disease Genes in Canada; Steering Committee consists of Kym Boycott (leader; Ottawa, Ontario), Jan Friedman (co-leader; Vancouver, British Columbia), Jacques Michaud (co-leader; Montreal, Quebec), Francois Bernier (Calgary, Alberta), Michael Brudno (Toronto, Ontario), Bridget Fernandez (St Johns, Newfoundland), Bartha Knoppers (Montreal, Quebec), Mark Samuels (Montreal, Quebec), Steve Scherer (Toronto, Ontario). We also thank Janet Marcadier (Clinical Coordinator) and Chandree Beaulieu (Project Manager) for their contribution to the infrastructure of the FORGE Canada Consortium. FORGE was funded by the Government of Canada through the Canadian Institutes of Health Research (EAS), Genome Canada, Genome Quebec, Genome British Columbia and the Ontario Genomics Institute (OGI-049). This work was supported by the âAssociation pour le DÃ©veloppement de la Recherche MÃ©dicale au Centre Hospitalier Universitaire de Marseilleâ (ADEREM).</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quentien</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Delemer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Papadimitriou</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Souchon</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Jaussaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pagnier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Munzer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jullien</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Reynaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Galon-Faure</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Enjalbert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barlier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brue</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Deficit in anterior pituitary function and variable immune deficiency (DAVID) in children presenting with adrenocorticotropin deficiency and severe infections</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <issue>1</issue>
          <fpage>E121</fpage>
          <lpage>E128</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2011-0407</pub-id>
          <?supplied-pmid 22013103?>
          <pub-id pub-id-type="pmid">22013103</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Younes</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Secord</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Panhypopituitarism in a child with common variable immunodeficiency</article-title>
          <source>Ann Allergy Asthma Immunol</source>
          <year>2002</year>
          <volume>89</volume>
          <issue>3</issue>
          <fpage>322</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="doi">10.1016/S1081-1206(10)61963-1</pub-id>
          <?supplied-pmid 12269656?>
          <pub-id pub-id-type="pmid">12269656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tovo</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Lala</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Martino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pastorelli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>De Sanctis</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Isolated adrenocorticotropic hormone deficiency associated with common variable immunodeficiency</article-title>
          <source>Eur J Pediatr</source>
          <year>1991</year>
          <volume>150</volume>
          <issue>6</issue>
          <fpage>400</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="doi">10.1007/BF02093717</pub-id>
          <?supplied-pmid 1645668?>
          <pub-id pub-id-type="pmid">1645668</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Coonrod</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Kumanovics</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Franks</surname>
              <given-names>ZF</given-names>
            </name>
            <name>
              <surname>Durtschi</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Margraf</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Heikal</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Augustine</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Ridge</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Jorde</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Weyrich</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Zimmerman</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Gundlapalli</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Bohnsack</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Voelkerding</surname>
              <given-names>KV</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway in the pathogenesis of common variable immunodeficiency</article-title>
          <source>Am J Hum Genet</source>
          <year>2013</year>
          <volume>93</volume>
          <issue>5</issue>
          <fpage>812</fpage>
          <lpage>824</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2013.09.009</pub-id>
          <?supplied-pmid 24140114?>
          <pub-id pub-id-type="pmid">24140114</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Fulcher</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Whittle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chand</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fewings</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Field</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Goodnow</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100</article-title>
          <source>Blood</source>
          <year>2014</year>
          <volume>124</volume>
          <issue>19</issue>
          <fpage>2964</fpage>
          <lpage>2972</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2014-06-578542</pub-id>
          <?supplied-pmid 25237204?>
          <pub-id pub-id-type="pmid">25237204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindsley</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Valencia</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Assa'ad</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Combined immune deficiency in a patient with a novel NFKB2 mutation</article-title>
          <source>J Clin Immunol</source>
          <year>2014</year>
          <volume>34</volume>
          <issue>8</issue>
          <fpage>910</fpage>
          <lpage>915</lpage>
          <pub-id pub-id-type="doi">10.1007/s10875-014-0095-3</pub-id>
          <?supplied-pmid 25205549?>
          <pub-id pub-id-type="pmid">25205549</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gurugama</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Novel NFKB2 mutation in early-onset CVID</article-title>
          <source>J Clin Immunol</source>
          <year>2014</year>
          <volume>34</volume>
          <issue>6</issue>
          <fpage>686</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="doi">10.1007/s10875-014-0064-x</pub-id>
          <?supplied-pmid 24888602?>
          <pub-id pub-id-type="pmid">24888602</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Majewski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwartzentruber</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Caqueret</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Patry</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marcadier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fryns</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Boycott</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Ste-Marie</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>McKiernan</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Marik</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Van Esch</surname>
              <given-names>H</given-names>
            </name>
            <collab>FORGE Canada Consortium</collab>
            <name>
              <surname>Michaud</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Samuels</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Mutations in NOTCH2 in families with Hajdu-Cheney syndrome</article-title>
          <source>Hum Mutat</source>
          <year>2011</year>
          <volume>32</volume>
          <issue>10</issue>
          <fpage>1114</fpage>
          <lpage>1117</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.21546</pub-id>
          <?supplied-pmid 21681853?>
          <pub-id pub-id-type="pmid">21681853</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Budry</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Balsalobre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Khetchoumian</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>L'Honore</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vallette</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brue</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Figarella-Branger</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Meij</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Drouin</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling</article-title>
          <source>Genes Dev</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>20</issue>
          <fpage>2299</fpage>
          <lpage>2310</lpage>
          <pub-id pub-id-type="doi">10.1101/gad.200436.112</pub-id>
          <?supplied-pmid 23070814?>
          <pub-id pub-id-type="pmid">23070814</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reynaud</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gueydan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saveanu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vallette-Kasic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Enjalbert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brue</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Barlier</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Genetic screening of combined pituitary hormone deficiency: experience in 195 patients</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2006</year>
          <volume>91</volume>
          <issue>9</issue>
          <fpage>3329</fpage>
          <lpage>3336</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-2173</pub-id>
          <?supplied-pmid 16735499?>
          <pub-id pub-id-type="pmid">16735499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Locatelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lugaresi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zerial</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bensa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pocecco</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Isolated adrenocorticotropic hormone deficiency in a child with common variable immunodeficiency</article-title>
          <source>European Society for Paediatric Endocrinology 45th Annual Meeting</source>
          <year>2006</year>
          <publisher-loc>Rotterdam</publisher-loc>
          <publisher-name>Hormone Research in Pediatrics</publisher-name>
          <fpage>36</fpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>The noncanonical NF-kappaB pathway</article-title>
          <source>Immunol Rev</source>
          <year>2012</year>
          <volume>246</volume>
          <issue>1</issue>
          <fpage>125</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01088.x</pub-id>
          <?supplied-pmid 22435551?>
          <pub-id pub-id-type="pmid">22435551</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Harhaj</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100</article-title>
          <source>Mol Cell</source>
          <year>2001</year>
          <volume>7</volume>
          <issue>2</issue>
          <fpage>401</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="doi">10.1016/S1097-2765(01)00187-3</pub-id>
          <?supplied-pmid 11239468?>
          <pub-id pub-id-type="pmid">11239468</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gloyn</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Edghill</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Harries</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Temple</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Hattersley</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Ellard</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2004</year>
          <volume>89</volume>
          <issue>8</issue>
          <fpage>3932</fpage>
          <lpage>3935</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2004-0568</pub-id>
          <?supplied-pmid 15292329?>
          <pub-id pub-id-type="pmid">15292329</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoppa-Vaucher</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ayabe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Paquette</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Patey</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Francoeur</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vuissoz</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Deladoey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Samuels</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Ogata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Deal</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>46, XY gonadal dysgenesis: new SRY point mutation in two siblings with paternal germ line mosaicism</article-title>
          <source>Clin Genet</source>
          <year>2012</year>
          <volume>82</volume>
          <issue>6</issue>
          <fpage>505</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1399-0004.2011.01832.x</pub-id>
          <?supplied-pmid 22288726?>
          <pub-id pub-id-type="pmid">22288726</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gauthier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Champagne</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>LafreniÃ¨re</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Spiegelman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brustein</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lapointe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>CÃ´tÃ©</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Noreau</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hamdan</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Addington</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Rapoport</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Delisi</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Krebs</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Joober</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fathalli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mouaffak</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Haghighi</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>NÃ©ri</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>DubÃ©</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Samuels</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Marineau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Awadalla</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Carbonetto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Drapeau</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rouleau</surname>
              <given-names>GA</given-names>
            </name>
            <collab>S2D Team</collab>
          </person-group>
          <article-title>De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2010</year>
          <volume>107</volume>
          <issue>17</issue>
          <fpage>7863</fpage>
          <lpage>7868</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0906232107</pub-id>
          <?supplied-pmid 20385823?>
          <pub-id pub-id-type="pmid">20385823</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kara-Mostefa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raoul</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Lyonnet</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Amiel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Munnich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vekemans</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Magnier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ossareh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bonnefont</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Recurrent Williams-Beuren syndrome in a sibship suggestive of maternal germ-line mosaicism</article-title>
          <source>Am J Hum Genet</source>
          <year>1999</year>
          <volume>64</volume>
          <issue>5</issue>
          <fpage>1475</fpage>
          <lpage>1478</lpage>
          <pub-id pub-id-type="doi">10.1086/302362</pub-id>
          <?supplied-pmid 10205282?>
          <pub-id pub-id-type="pmid">10205282</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rantamaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kaitila</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Syvanen</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Lukka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peltonen</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Recurrence of Marfan syndrome as a result of parental germ-line mosaicism for an FBN1 mutation</article-title>
          <source>Am J Hum Genet</source>
          <year>1999</year>
          <volume>64</volume>
          <issue>4</issue>
          <fpage>993</fpage>
          <lpage>1001</lpage>
          <pub-id pub-id-type="doi">10.1086/302309</pub-id>
          <?supplied-pmid 10090884?>
          <pub-id pub-id-type="pmid">10090884</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tucker</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>O'Donnell</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fuchsberger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hilton</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Metcalf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Greig</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sims</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Quinn</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Hilton</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Kile</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Tarlinton</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Starr</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A novel mutation in the Nfkb2 gene generates an NF-kappa B2 "super repressor"</article-title>
          <source>J Immunol</source>
          <year>2007</year>
          <volume>179</volume>
          <issue>11</issue>
          <fpage>7514</fpage>
          <lpage>7522</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.179.11.7514</pub-id>
          <?supplied-pmid 18025196?>
          <pub-id pub-id-type="pmid">18025196</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mordmuller</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Krappmann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Esen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wegener</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Scheidereit</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism</article-title>
          <source>EMBO Rep</source>
          <year>2003</year>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>82</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.embor.embor710</pub-id>
          <?supplied-pmid 12524526?>
          <pub-id pub-id-type="pmid">12524526</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dejardin</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development</article-title>
          <source>Biochem Pharmacol</source>
          <year>2006</year>
          <volume>72</volume>
          <issue>9</issue>
          <fpage>1161</fpage>
          <lpage>1179</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2006.08.007</pub-id>
          <?supplied-pmid 16970925?>
          <pub-id pub-id-type="pmid">16970925</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheinman</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Beg</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Baldwin</surname>
              <given-names>AS</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule</article-title>
          <source>Mol Cell Biol</source>
          <year>1993</year>
          <volume>13</volume>
          <issue>10</issue>
          <fpage>6089</fpage>
          <lpage>6101</lpage>
          <?supplied-pmid 8413211?>
          <pub-id pub-id-type="pmid">8413211</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ware</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Siebenlist</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>YX</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway</article-title>
          <source>J Clin Invest</source>
          <year>2006</year>
          <volume>116</volume>
          <issue>11</issue>
          <fpage>2964</fpage>
          <lpage>2971</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI28326</pub-id>
          <?supplied-pmid 17039258?>
          <pub-id pub-id-type="pmid">17039258</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kuroishi</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Osawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nagano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Weih</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Doi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ohya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Katagiri</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hosokawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jimi</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Accumulation of p100, a precursor of NF-kappaB2, enhances osteoblastic differentiation in vitro and bone formation in vivo in aly/aly mice</article-title>
          <source>Mol Endocrinol</source>
          <year>2012</year>
          <volume>26</volume>
          <issue>3</issue>
          <fpage>414</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="doi">10.1210/me.2011-1241</pub-id>
          <?supplied-pmid 22282470?>
          <pub-id pub-id-type="pmid">22282470</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyce</surname>
              <given-names>BF</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Franzoso</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Siebenlist</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Required and nonessential functions of nuclear factor-kappa B in bone cells</article-title>
          <source>Bone</source>
          <year>1999</year>
          <volume>25</volume>
          <issue>1</issue>
          <fpage>137</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1016/S8756-3282(99)00105-2</pub-id>
          <?supplied-pmid 10423039?>
          <pub-id pub-id-type="pmid">10423039</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McEachern</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Drouin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Metherell</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Huot</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Van Vliet</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Deal</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Severe cortisol deficiency associated with reversible growth hormone deficiency in two infants: what is the link?</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2011</year>
          <volume>96</volume>
          <issue>9</issue>
          <fpage>2670</fpage>
          <lpage>2674</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2011-0129</pub-id>
          <?supplied-pmid 21752888?>
          <pub-id pub-id-type="pmid">21752888</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benoit</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lapeyraque</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sartelet</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Saint-Cyr</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Le Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Haddad</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Renal granuloma and immunoglobulin M-complex glomerulonephritis: a case of common variable immunodeficiency?</article-title>
          <source>Pediatr Nephrol</source>
          <year>2009</year>
          <volume>24</volume>
          <issue>3</issue>
          <fpage>601</fpage>
          <lpage>604</lpage>
          <pub-id pub-id-type="doi">10.1007/s00467-008-0958-z</pub-id>
          <?supplied-pmid 18696117?>
          <pub-id pub-id-type="pmid">18696117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Hasselmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Samuels</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Van Vliet</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Goliath, a Variant of DAVID Syndrome?</article-title>
          <source>53rd Annual Meeting of the European Society of Pediatric Endocrinology</source>
          <year>2014</year>
          <publisher-loc>Dublin</publisher-loc>
          <publisher-name>European Society of Pediatric Endocrinology</publisher-name>
          <fpage>283</fpage>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deal</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hasselmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pfaffle</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Quigley</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Child</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Shavrikova</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>GB</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Blum</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study</article-title>
          <source>Horm Res Paediatr</source>
          <year>2013</year>
          <volume>79</volume>
          <issue>5</issue>
          <fpage>283</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="doi">10.1159/000350829</pub-id>
          <?supplied-pmid 23689058?>
          <pub-id pub-id-type="pmid">23689058</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rabson</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Qing</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease</article-title>
          <source>Cytokine Growth Factor Rev</source>
          <year>2006</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>281</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cytogfr.2006.04.005</pub-id>
          <?supplied-pmid 16793322?>
          <pub-id pub-id-type="pmid">16793322</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baud</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2009</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>33</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1038/nrd2781</pub-id>
          <?supplied-pmid 19116625?>
          <pub-id pub-id-type="pmid">19116625</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>